Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Lab Testing Responsive support Support team answers order and product questions
Cagrilintide (AM833) is a long-acting synthetic amylin and calcitonin receptor agonist studied in metabolic research
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
Not for human consumption, medical use, diagnostic applications, veterinary use, or any other in-vivo application
Swab the rubber septum with 70% isopropyl alcohol before each needle entry and allow to dry before insertion
HSA and FSA use depends on the individual plan administrator
-1775582746855.png&w=3840&q=75)
.png)
